Systemic Therapies for Pediatric Atopic Dermatitis

a study on Atopic Dermatitis (Eczema)

Summary

for people ages 2-17 (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Kelly M. Cordoro, MDIlona J. Frieden, MDJeffrey Sugarman

Description

Summary

While many patients with atopic dermatitis (eczema) can be managed with topical creams and treatments for itch, some children have such severe, long-standing disease that they need treatment with oral medications that decrease the ability of the immune system to react. However, there is not enough information on the proper use of these medications or how well they work compared with each other. The current study looks at the response of children treated with these medications to provide this information and improve their use.

Details

Severe and/or refractory cases of atopic dermatitis (AD) can require systemic immunosuppressive therapy for disease control, yet there are few studies regarding the appropriate use of these drugs for pediatric AD and even less data comparing them. The current observational study will observe the effect of these therapies on children with moderate to severe atopic dermatitis as they are treated. These drugs being observed will be cyclosporine, azathioprine, mycophenolate mofetil, and methotrexate.

Keywords

Dermatitis, Atopic Dermatitis Azathioprine mycophenolate mofetil cyclosporine methotrexate

Eligibility

You can join if…

Open to people ages 2-17

  • Diagnosis of moderate, severe, or very severe atopic dermatitis meeting the Hanifin and Rajka criteria
  • Needs systemic therapy (e.g. cyclosporine, azathioprine, mycophenolate mofetil, or methotrexate) for severe atopic dermatitis
  • Subject has severe or recalcitrant disease interrupting daily life as evidenced by fulfilling 2 or more of the following 4 criteria:
  • Failure of multimodal therapy including emollients/barrier repair, topical anti-inflammatory agents (medium to high potency topical corticosteroids, and/or low-potency or topical calcineurin inhibitors if facial/intertriginous areas), and antihistamines
  • Significant impairment in quality of life (physical, psychological, emotional) such as significant sleep disruption, poor school performance, or frequent school absenteeism, per the judgement of the investigator.
  • Inability to receive, prior failure, or the need for more than one course of phototherapy
  • Prior failure or need for more than one course of another oral immunosuppressive medication
  • No serious medical condition that precludes the use of oral immunosuppressives based on the subject's medical history, physical examination, and safety laboratory tests.
  • Negative PPD within the last year prior to study initiation.
  • Female of childbearing potential has a negative pregnancy test at the time of starting the systemic drug and who consents to be abstinent or using an effective method of contraception during the study. Effective contraception is defined as IUD, condom with spermicide, diaphragm with spermicide, or stable use of a hormonal contraceptive (oral, implant, injection or transdermal patch) beginning at least 1 month prior to starting the systemic drug.
  • Subject and parent/guardian are willing and able to comply with study instructions and return to the clinic for all required visits.

You CAN'T join if...

  • Female who is pregnant, nursing, or planning a pregnancy during the study period.
  • Concurrent participation in another clinical trial with an investigational drug or device that may impact on the individual's atopic dermatitis.
  • Subjects with clinically significant hepatic disease, history of lymphoma or myelosuppression, low TMPT activity (if starting azathioprine), renal disease (if starting cyclosporine or azathioprine), hypertension (if starting cyclosporine), blood dyscrasias, or central nervous system disorders, such as uncontrolled seizures or peripheral neuropathy, or taking systemic medications that could interact adversely with the study medicine (e.g. erythromycin use with cyclosporine).
  • Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for subject safety while participating on the study.
  • Subject has a history of clinically significant drug or alcohol abuse in the last year.
  • Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
  • Active systemic infection that could worsen with systemic therapy for AD.

Locations

  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States
  • Rady Children's Hospital accepting new patients
    San Diego California 92123 United States

Lead Scientists

  • Kelly M. Cordoro, MD
    Dr. Kelly Cordoro is a Professor of Dermatology and Pediatrics at the University of California, San Francisco. She is Division Chief of Pediatric Dermatology and the Pediatric Dermatology Fellowship Director at UCSF. Dr. Cordoro’s clinical focus is complex medical dermatology, particularly inflammatory diseases, in children. Her primary research interest is pediatric psoriasis.
  • Ilona J. Frieden, MD
    I have been a member of the full-time faculty at UCSF since 1989. I am Professor of Clinical Dermatology and Pediatrics, a founding member of the Division of Pediatric Dermatology, and Vice-Chair of Dermatology. My main research areas are in studying vascular birthmarks, particularly infantile hemangiomas.
  • Jeffrey Sugarman

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Rady Children's Hospital, San Diego
ID
NCT01447381
Study Type
Observational
Last Updated